Accropeutics Bioscience, a China-based clinical-stage biotech company, announced on Wednesday that the company has received approval from the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial of its oral small molecule TYK2/JAK1 inhibitor AC-201 in Australia.
The trial, a randomised, double-blind, placebo-controlled, single and multiple ascending dose study, is to assess the safety, tolerability, pharmacokinetics, and food impacts of AC-201 in healthy adults.
AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have indicated that the product effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1, stabilising the self-inhibitory conformation of the pseudo kinase domain on the kinase domain, thereby inhibiting the function of TYK2/JAK1 kinase. It showcased significant efficacy in multiple animal models of diseases, including psoriasis, and is aimed at the treatment of psoriasis and other inflammatory and autoimmune diseases. The company said that it is expected to provide convenience and efficacy with good safety for psoriasis patients.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients